The safety and efficacy of Hizentra self-infusions have been proven in patients age 2 and older.

Proven protection against infection

Zero serious infections

Hizentra delivered low rates of infection in a 12-month study with zero serious infections that could potentially require hospitalization, like bacterial pneumonia, bacteremia/ septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

2.76 overall inductions

The same 12-month study found an average of 2.76 overall infections per subject-year.

2 missed days/year

People taking Hizentra missed about 2 days of work or school per year due to infections (2.06 days per person per year on average in clinical studies).

Subcutaneous Immunoglobulin (SCIg) Infusion Experience

Subcutaneous Immunoglobulin (SCIg) Infusion Experience


  • Retired teacher and librarian
  • Diagnosed with PI in 1999
  • Enjoying her independence using Hizentra prefilled syringes
Watch Video

Demonstrated safety in PI

No serious side effects

In a 12-month study of people taking Hizentra, there were no serious side effects related to treatment.

Two subjects withdrew from the study due to non-serious side effects. Please see full Important Safety Information below, including boxed warning.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible.

Safe protection since 2010

The only SCIg that has been providing protection against infection since 2010.

You are now leaving the current website.

Do you want to continue?

No Yes